Zobrazeno 1 - 10
of 439
pro vyhledávání: '"Kyu pyo Kim"'
Autor:
Bhumsuk Keam, Chan-Young Ock, Do-Youn Oh, Seung-Tae Kim, Keun-Wook Lee, Sun Young Rha, Changhoon Yoo, John Park, Min Hwan Kim, Sehyun Kim, Dhanusha Sabanathan, Joon Oh Park, Napa Parinyanitikul, Kyu Pyo Kim, Jaebong Yoon, Hyelim Lim, Sangheon Lee, Wooick Jang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/5009271548a74b489eadc49eed000e3d
Autor:
Do-Youn Oh, Anthony W Tolcher, Kyu Pyo Kim, Hyesung Shin, Huntaek Kim, Soo Jin Kim, Eunsun Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/328ba34ef6b94c3e9dbfd50d5e2e5942
Autor:
Ho Yong Kim, Hyun-Ki Min, Hyeong-Woo Song, Ami Yoo, Seonmin Lee, Kyu-Pyo Kim, Jong-Oh Park, You Hee Choi, Eunpyo Choi
Publikováno v:
Drug Delivery, Vol 29, Iss 1, Pp 2897-2911 (2022)
Exosomes are nanosized extracellular vesicles secreted by various cell types, including those of the immune system, such as natural killer (NK) cells. They play a role in intercellular communication by transporting signal molecules between the cells.
Externí odkaz:
https://doaj.org/article/252428bde0614c25ac02551e85074647
Autor:
Sora Kang, Jae Ho Jeong, Shinkyo Yoon, Changhoon Yoo, Kyu-pyo Kim, Hyungwoo Cho, Baek-Yeol Ryoo, Jinhong Jung, Jeong Eun Kim
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Cancer of unknown primary (CUP) is a heterogeneous malignancy in which the primary site of the tumor cannot be identified through standard work-up. The survival outcome of CUP is generally poor, and there is no consensus for treatment. Here,
Externí odkaz:
https://doaj.org/article/8d52adec9532400fb509dd2322c3ccfb
Autor:
Hye‐Young Min, Jaebeom Cho, Jeong Yeon Sim, Hye‐Jin Boo, Ji‐Sun Lee, Seon‐Boon Lee, Young‐Jin Lee, Sung Joo Kim, Kyu‐Pyo Kim, In‐Ja Park, Seung‐Mo Hong, Xue‐Li Zhang, Zhi‐Gang Zhang, Rang‐Woon Park, Ho‐Young Lee
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 7, Pp n/a-n/a (2022)
Abstract Background Programmed death‐ligand 1 (PD‐L1) has functional roles in cancer stem‐like cell (CSC) phenotypes and chemoresistance besides immune evasion. Chemotherapy is a common treatment choice for colorectal cancer (CRC) patients; how
Externí odkaz:
https://doaj.org/article/7c30c7044e43480a9579cda7dfd51674
Autor:
Yeong Hak Bang, Jeong Eun Kim, Ji Sung Lee, Sun Young Kim, Kyu-Pyo Kim, Tae Won Kim, Yong Sang Hong
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a
Externí odkaz:
https://doaj.org/article/90406605d8d147a48bfed13fe0d89c7a
Autor:
Woohyung Lee, Minyoung Oh, Jae Seung Kim, Minkyu Sung, Kwangpyo Hong, Bong Jun Kwak, Yejong Park, Eunsung Jun, Ki Byung Song, Dae Wook Hwang, Jae Hoon Lee, Changhoon Yoo, Kyu-Pyo Kim, Inkeun Park, Jae Ho Jeong, Heung-Moon Chang, Baek-Yeol Ryoo, Jung Bok Lee, Song Cheol Kim
Publikováno v:
International Journal of Surgery; Jul2024, Vol. 110 Issue 7, p4074-4082, 9p
Autor:
Sora Kang, Changhoon Yoo, So Heun Lee, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Jae Ho Jeong, Do Hyun Park, Dong Wan Seo, Jin-hong Park, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Bong Jun Kwak, Sarang Hong, Heung-Moon Chang, Baek-Yeol Ryoo, Kyu-pyo Kim, Song Cheol Kim
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Adjuvant chemotherapy is the standard treatment after curative-intent surgery for pancreatic ductal adenocarcinoma (PDAC). The phase-3 ESPAC-4 trial demonstrated significantly improved overall survival (OS) with Gemcitabine plus capecitab
Externí odkaz:
https://doaj.org/article/e942281ca3ca4e8a8b4a6d4a9d6b8278
Autor:
Jihyun Chun, Yeon Wook Kim, Seo-rin Jeong, Hyung Jun Cho, Kyu-Pyo Kim, Dae Wook Hwang, Seung-Mo Hong
Publikováno v:
Human Pathology. 137:36-47
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fed3b91a717892b4441100b59b28b136
https://doi.org/10.1016/j.humpath.2023.04.008
https://doi.org/10.1016/j.humpath.2023.04.008
Autor:
You-Na Sung, Sung Joo Kim, Sun-Young Jun, Changhoon Yoo, Kyu-Pyo Kim, Jae Hoon Lee, Dae Wook Hwang, Shin Hwang, Sang Soo Lee, Seung-Mo Hong
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundGallbladder cancer (GBC) has a poor prognosis. Although complete surgical resection is the only successful approach for improving survival, additional therapeutic modalities are required for recurrent or surgically unresectable GBCs.Materia
Externí odkaz:
https://doaj.org/article/d591750419c2493a8afede64cfd0740b